NFKB1 and sarcopenia: Butyrate potently antagonizes chronic, low-grade inflammation, a key driver of sarcopenia, by inhibiting the NF-κB pathway and subsequent production of pro-inflammatory cytokines such as IL-6 (Van et al., 2024).